Analysis of differentially expressed genes in lncap prostate cancer progression model

Journal of Andrology

Volumn 32, Issue 2, 2011, Pages 170-182

  Xie, Bang Xiang ^a,b   Zhang, Hui ^a   Wang, Jian ^a   Pang, Bo ^a   Wu, Rui Qin ^a   Qian, Xiao Long ^a   Yu, Lan ^a   Li, Shan Hu ^a   Shi, Qing Guo ^a   Huang, Cui Fen ^a   Zhou, Jian Guang ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

cDNA microarray; LNCaP C4 2

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; COMPLEMENTARY DNA; FIBRONECTIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE; RNA; TRANSCRIPTION FACTOR;

ARTICLE; CELL SPECIFICITY; CELL STRAIN LNCAP; DNA MICROARRAY; FATTY ACID METABOLISM; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; WESTERN BLOTTING;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS;

EID: 80455174381     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.109.008748     Document Type: Article

References (29)

1. Agalliu I, Suuriniemi M, Prokunina-Olsson L, Johanneson B, Collins FS, Stanford JL, Ostrander EA. Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study. Prostate. 2008;68:740-747.
2. Balaji KC, Rao PS, Smith DJ, Louis S, Smith LM, Sherman S, Bacich D, O'Keefe D. Microarray analysis of differential gene expression in androgen independent prostate cancer using a metastatic human prostate cancer cell line model. Urol Oncol. 2004;22:313-320.
3. Devilard E, Bladou F, Ramuz O, Karsenty G, Dalès JP, Gravis G, Nguyen C, Bertucci F, Xerri L, Birnbaum D. FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer. 2006;6:272.
4. el-DeiryWS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
5. Graham SM, Oldham SM, Martin CB, Drugan JK, Zohn IE, Campbell S, Der CJ. TC21 and Ras share indistinguishable transforming and differentiating activities. Oncogene. 1999;18:2107-2116.
6. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell. 1993;75:805-816.
7. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64: 825-829.
8. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809-1818.
9. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science. 1986;233:467-470.
10. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
11. Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate. 2004;58:183-192.
12. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS. Sex-determining regionY box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 2006;66:4011-4019.
13. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230-234..
14. Marelli MM, Moretti RM, Procacci P, Motta M, Limonta P. Insulinlike growth factor-I promotes migration in human androgenindependent prostate cancer cells via the avb3 integrin and PI3-K/Akt signaling. Int J Oncol. 2006;28:723-730.
15. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis. 2006;27:1-22.
16. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 2001;61:6276-6280.
17. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer. 2005;92:2171-2180.
18. Rong R, He Q, Liu Y, Sheikh MS, Huang Y. TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kB signaling pathway. Oncogene. 2002;21:1062-1070.
19. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen independent model of prostate cancer. Cancer Res. 2003;63:2306-2311.
20. Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, Jonatan D, Zorn AM, Wells JM. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007;27:7802-7815.
21. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res. 2006;12:4357-4362.
22. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54:2577-2581.
23. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate. 2000;44:91-103.
24. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP, Yuan X. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68:1625-1630.
25. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994;57:406-412.
26. Yamaguchi A, Taniguchi M, Hori O, Ogawa S, Tojo N, Matsuoka N, Miyake S, Kasai K, Sugimoto H, Tamatani M, Yamashita T, Tohyama M. Peg3/Pw1 is involved in p53-mediated cell death pathway in brain ischemia/hypoxia. J Biol Chem. 2002;277:623-629.
27. Yousef GM, Scorilas A, Jung K, Ashworthi LK, Diamandis EP. Molecular cloning of the human kallikrein 15 gene (KLK15). J Biol Chem. 2001;276:53-61.
28. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB. a-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 2003;63:7365-7376.
29. Zhang H, Wang J, Pang B, Liang RX, Li S, Huang PT, Wang R, Chung LW, Zhau HE, Huang C, Zhou JG. PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res. 2007; 67:8906-8913.